Key points are not available for this paper at this time.
The aim of this study was to evaluate the efficacy and safety of peptide-targeted radionuclide therapy (PTRT) with 177Lu-FAP-2286 in advanced lung cancer.
Xie et al. (Sun,) studied this question.